Economic evaluation of low-dose rivaroxaban adding on aspirin for the patients with stable cardiovascular disease from the perspective of Taiwan national payers
Event:
ESC Asia with APSC & AFC
Topic:
Health Economics
Session:
Poster Session Saturday 1